Thomas Laney, MD
Family Medicine · Conover, NCNPI 1891753687
Payments from drug & device makers
Across 311 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$931
- Lilly USA, LLC$697
- AstraZeneca$482
- Bayer$264
- Amgen$245
- Boehringer Ingelheim$244
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,865100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 72 | $931 |
| Lilly USA, LLC | 41 | $697 |
| AstraZeneca | 30 | $482 |
| Bayer | 13 | $264 |
| Amgen | 14 | $245 |
| Boehringer Ingelheim | 15 | $244 |
| Pfizer | 12 | $191 |
| Johnson & Johnson | 10 | $156 |
| Merck | 11 | $142 |
| Abbott | 7 | $139 |
| Nestle Healthcare Nutrition Inc. | 8 | $110 |
| Kaleo, Inc. | 6 | $107 |
| Teva Pharmaceuticals USA, Inc. | 8 | $103 |
| Novartis | 5 | $93 |
| Sanofi-aventis U.S. LLC | 5 | $86 |
| Supernus Pharmaceuticals, Inc. | 5 | $79 |
| Exact Sciences | 4 | $77 |
| Ironshore Pharmaceuticals Inc. | 4 | $65 |
| Amarin Pharma, Inc. | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 4 | $52 |
| Organon | 4 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Almatica Pharma LLC | 3 | $43 |
| Tris Pharma Inc | 3 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| IBSA Pharma Inc. | 2 | $31 |
| Eisai Inc. | 2 | $30 |
| AbbVie | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Ionis Pharmaceuticals, Inc. | 1 | $19 |
| Tolmar, Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| USWM, LLC | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| GSK | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$4,865 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 101 | $102,577 |
| FarxigaDapagliflozin Propanediol | 58 | $50,763 |
| JanuviaSitagliptin Phosphate | 23 | $31,561 |
| RybelsusSemaglutide | 31 | $31,015 |
| EliquisApixaban | 19 | $22,234 |
| ZenpepLipase/Protease/Amylase | 14 | $21,855 |
| XareltoRivaroxaban | 19 | $20,048 |
| TrulicityDulaglutide | 15 | $15,266 |
| OzempicSemaglutide | 16 | $15,071 |
| MounjaroTirzepatide | 13 | $13,422 |
| LinzessLinaclotide | 17 | $9,012 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $8,303 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $7,734 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $6,767 |
| Fluticasone Propionate | 58 | $5,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $244 | $102,577101 claims |
| AstraZenecaFarxiga, Symbicort | $482 | $58,49786 claims |
| Novo NordiskRybelsus, Ozempic | $931 | $46,08647 claims |
| MerckJanuvia, Janumet Xr | $142 | $38,32835 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $697 | $28,68828 claims |
| PfizerEliquis | $191 | $22,23419 claims |
| Aimmune Therapeutics, Inc.Zenpep | $17 | $21,85514 claims |
| Johnson & JohnsonXarelto | $156 | $20,04819 claims |
| AbbVieLinzess | $27 | $9,01217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Conover
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.